Zura Bio Limited (NASDAQ:ZURA) Receives $10.75 Average Target Price from Brokerages

Shares of Zura Bio Limited (NASDAQ:ZURA) have received an average rating of “Moderate Buy” from the seven research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $10.75.

Several research firms have recently issued reports on ZURA. Wedbush reiterated an “outperform” rating and set a $15.00 target price on shares of Zura Bio in a report on Wednesday, July 1st. Wall Street Zen downgraded Zura Bio from a “sell” rating to a “strong sell” rating in a research note on Sunday, July 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a research note on Monday, July 6th. Finally, William Blair started coverage on Zura Bio in a research report on Wednesday, July 8th. They set an “outperform” rating for the company.

Zura Bio Price Performance

NASDAQ:ZURA opened at $5.23 on Thursday. The firm’s 50-day moving average price is $4.55 and its 200-day moving average price is $5.37. The company has a market capitalization of $496.22 million, a PE ratio of -4.80 and a beta of -0.03. Zura Bio has a 1-year low of $1.35 and a 1-year high of $7.44.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.05). Equities analysts anticipate that Zura Bio will post -0.76 EPS for the current fiscal year.

Institutional Investors Weigh In On Zura Bio

Institutional investors have recently modified their holdings of the stock. Allworth Financial LP bought a new position in shares of Zura Bio during the fourth quarter valued at $30,000. Scientech Research LLC bought a new position in Zura Bio in the 3rd quarter worth about $45,000. AQR Capital Management LLC bought a new position in Zura Bio in the 1st quarter worth about $72,000. Bank of America Corp DE grew its position in Zura Bio by 31.9% during the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after purchasing an additional 9,966 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in Zura Bio during the 3rd quarter valued at about $109,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.